Arthur Kuan, CG Oncology CEO

Can an on­colyt­ic virus ther­a­py chal­lenge the stan­dard of care in blad­der can­cer? CG On­col­o­gy has $120M to find out

CG On­col­o­gy is cash­ing in on its in­ter­im da­ta up­date.

Tues­day morn­ing, the Irvine, CA-based biotech an­nounced that it raised $120 mil­lion — eclips­ing the com­bined $87 mil­lion it’s brought in since its in­cep­tion 12 years ago. The raise comes af­ter CG post­ed up­dat­ed da­ta at SITC for its on­colyt­ic virus can­di­date in com­bi­na­tion with Keytru­da for non-mus­cle in­va­sive blad­der can­cer, or NMIBC, in pa­tients who did not re­spond to stan­dard Bacil­lus Cal­mette-Guérin (BCG) ther­a­py.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.